Who’s buying healthcare AI startups?
Everything we know about the healthcare AI market, in one place. Get our report whether you build or invest.
Summary
Healthcare AI startups are being bought mainly by healthcare-native companies: software platforms, diagnostics and life-sciences groups, medtech companies and increasingly AI-native health platforms that already control customers, workflows or clinical distribution. Agilent’s October 2026 agreement to buy pathology platform Proscia and Azra AI’s purchase of Blackford Analysis are the newest examples.
Big Tech is not driving this market. OpenAI’s Torch deal is notable, but apart from Sopris Capital’s brief ownership of Blackford, the named healthcare AI deals of September and October 2026 all had healthcare or life-sciences buyers looking to add a missing capability to an existing platform. Who leads healthcare AI, specialists or big tech, is shown on the market maps in our healthcare AI market report.
The exit market is increasingly an M&A market. Rock Health counted 195 U.S. digital-health acquisitions in 2025 and 115 in the first half of 2026, while Galen Growth found that 82 of 84 digital-health exits in the first half of 2026 were acquisitions.
Revenue-cycle AI stands out because the acquisition case can be tied directly to money: fewer denials, less administrative labor and faster reimbursement. That makes prior authorization, coding, documentation and claims automation unusually easy for strategic buyers to justify.
Diagnostics and pathology AI can command much larger prices because buyers are not only acquiring software. They are buying regulated products, proprietary clinical data, laboratory workflows, clinical evidence and relationships that can take years to rebuild. Agilent’s Proscia agreement, $240 million in cash at closing plus up to $30 million tied to milestones, is the newest disclosed price; it has not closed yet.
The model itself is becoming less central to the acquisition thesis. The harder assets to copy are increasingly the data, installed workflow, customer base, regulatory position and distribution that sit around the model.
Hospitals and insurers are important to healthcare AI without being the main acquirers. They more often act as customers, deployment partners, investors and validation environments while specialist technology companies do the consolidating.
Partnerships are quietly becoming part of the exit path. Roche worked with PathAI for years before agreeing to buy it, Tempus invested in and commercialized Personalis technology before moving to acquire it, and Agilent had distributed Proscia’s software since September 2022.
Private equity is participating, often by assembling platforms, as Sopris Capital did with Blackford and Azra AI. Strategic buyers still have the stronger reason to pay. A healthcare platform can usually point to a specific workflow, dataset, customer segment or revenue stream that the target immediately improves.
The next wave is likely to favor embedded B2B products over generic AI features. Smaller ambient-scribe companies, revenue-cycle tools, diagnostics businesses and AI products with real healthcare distribution look much easier to buy than companies whose main advantage is access to a model everyone else can also use.
The practical rule is simple: look first for the buyer that already owns hospital access, physician attention, claims infrastructure, diagnostic distribution or a large patient base. The most likely target is the AI company that fills the most expensive missing piece.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
A good product starts with a real problem. In our report covering the healthcare AI market, we show you the ones customers still live with.
What counts as a healthcare AI acquisition now?
Rock Health made that point explicitly in its latest quarterly work: it stopped tracking AI-enabled digital-health funding as a distinct category because AI had become standard across too many healthcare products. The same problem applies to M&A. PathAI is obviously an AI company. Humata Health clearly qualifies because its core product automates prior authorization with AI. But when Tempus AI buys cancer-testing company Personalis, or when an AI-native care platform buys a virtual-care company, the acquisition is also part of the healthcare AI consolidation story even if the target does not put “AI” at the center of its branding.
For this analysis, we care about acquisitions where AI is central to either the target’s product or the buyer’s reason for doing the deal. That captures the transactions reshaping the market without pretending that every digital-health acquisition is suddenly an AI acquisition. Our definition of what counts as healthcare AI, and what is only digital health, is explained in our report on healthcare AI.
We also separate signed agreements from completed deals, and core AI targets from adjacent automation. Agilent’s Proscia deal is signed but not closed. Zocdoc’s purchase of insurance-eligibility vendor Sohar Health, closed on October 2, 2026, and MRO’s purchase of document-intake company Vyne Medical are automation deals where AI is part of the product, not clearly its core.
Who is actually buying healthcare AI startups right now?
Healthcare AI startups are currently being bought mainly by healthcare software companies, diagnostics groups, medtech companies and AI-enabled health platforms that already sell into healthcare.
The aggregate numbers support that conclusion. Rock Health found that digital-health companies themselves made 66% of U.S. digital-health acquisitions in 2025, up from 53% the year before and the highest proportion in its dataset going back to 2013. Private equity came a distant second at 10%.
The latest deals point in the same direction. In October 2026, Agilent agreed to acquire Proscia, Azra AI completed its purchase of Blackford Analysis and Equiti bought Lexi, an AI medical-interpretation company. In September, DexCare bought Mila Health, whose AI agents schedule and coordinate care, and Hello Patient bought Converse Health, whose AI handles referrals, chart documentation and payer paperwork. Earlier in 2026, R1 agreed to acquire prior-authorization company Humata Health, Roche agreed to acquire PathAI for up to $1.05 billion and Tempus agreed to buy Personalis for an enterprise value of roughly $1.5 billion.
OpenAI’s purchase of Torch shows that a horizontal AI company can enter healthcare through M&A, but these deals remain much less common than acquisitions by companies already operating inside healthcare.
| Buyer type | What we are seeing now | Typical reason to buy |
|---|---|---|
| Healthcare software platforms | Very active | Add AI to an existing hospital or physician workflow |
| Diagnostics and medtech companies | Very active in specialized AI | Add proprietary data, regulated products and analysis tools |
| AI-native healthcare platforms | Increasingly active | Expand into adjacent care, diagnostics or data |
| Big Tech and frontier AI companies | Selective | Acquire healthcare-specific data or infrastructure |
| Private equity | Meaningful but secondary | Build larger platforms and modernize legacy healthcare assets |
| Hospitals and health systems | Rare as direct acquirers | Usually buy the product rather than the startup |
If you build or invest in the healthcare AI market, you need to know which business models pay off now and which ones are fading. That's why our report covering it has a whole section on it.
Why is healthcare AI M&A so active now?
Healthcare AI M&A is active today because acquisitions have become the easiest exit route for many startups while larger healthcare platforms are under pressure to broaden what they sell.
Two different datasets reach the same broad conclusion even though their methodologies differ. Rock Health counted 195 U.S. digital-health acquisitions in 2025, 61% more than in 2024. Its half-year numbers, reported by Fierce Healthcare, put the first half of 2026 at 115 acquisitions, slightly ahead of the previous year’s pace. Capstone Partners, also cited by Fierce in September 2026, counted 179 healthcare-IT deals in 2026 through September, up 23% year on year. Neither counts healthcare AI deals alone.
Galen Growth takes a broader global view and counts fewer transactions under its methodology, but the exit mix is even more striking. Its HealthTech Alpha data found that 82 of 84 digital-health exits in the first half of 2026 were acquisitions. That is 97.6%. Only one company in that dataset went public through a traditional IPO.
Buyers are also becoming choosier. Galen Growth found fewer M&A transactions in the first half of 2026 than a year earlier, while the average value among disclosed deals jumped to roughly $515 million from $301 million. Fewer transactions are absorbing more capital.
Are healthtech companies buying more healthcare AI startups than Big Tech?
Yes. Healthtech companies are currently much more important buyers of healthcare AI than Microsoft, Google, Amazon, Nvidia or the large foundation-model companies.
Galen Growth’s latest data gives us a useful measure of how strong this has become. Health Management Solutions companies accounted for 30.6% of venture-to-venture digital-health acquisitions in the first half of 2026, up from 16.7% in the same period four years earlier. These infrastructure companies have effectively doubled their share of startup-on-startup buying. Healthtech infrastructure doubling its share of startup buying is one of the market signals we follow every quarter in our market report about healthcare AI.
Recent deals fit that behavior almost perfectly. The strategic buyers named in September and October 2026, from Agilent to DexCare, all sell into healthcare or life sciences already. R1 is adding Humata’s prior-authorization automation to its revenue-cycle operating system. Experity bought Exdion to automate coding, billing and claims for urgent-care operators; Experity already serves nearly half of U.S. urgent-care clinics. Waystar previously bought Iodine Software because it could connect Iodine’s clinical intelligence with one of healthcare’s largest payment networks.
Big Tech can spend far more, but it has made far fewer direct healthcare AI acquisitions so far. No public census gives an exact ratio, so the gap shows up in named deals rather than in a precise count.
Why aren’t hospitals buying more healthcare AI startups themselves?
Hospitals are buying a lot of healthcare AI software today, but they rarely need to own the company that makes it.
A hospital gets most of the benefit by becoming a customer, running a pilot, investing through a venture arm or helping validate the technology. Owning the company means managing product development and outside customers far beyond the health system.
Recent health-system M&A supports this. Hospital buyers have remained heavily focused on physician groups, outpatient facilities and care-delivery assets. At the same time, health systems are becoming important launch partners for AI companies. Galen Growth’s latest work found that healthcare infrastructure represented 22.8% of health-system digital-health partnerships in the first half of 2026, up from 18.8% four years earlier.
The newest deals fit: MRO, Azra AI and DexCare sell to hospitals, and they did the buying. Hospitals often help create an attractive acquisition target without becoming the acquirer themselves.
Learning from others' mistakes is the cheapest lesson there is. In our market report about AI in healthcare, we look at what broke startups before you, so you don't repeat it.
Are health insurers buying healthcare AI startups?
Health insurers are still much more visible as customers, builders and investors in healthcare AI than as direct buyers of AI startups.
Payers have obvious uses for AI in claims processing, prior authorization, fraud detection, care navigation and member communication. Yet large insurers can already access those technologies through internal development, vendor contracts and strategic investments.
That helps explain why recent payer-related consolidation is often happening one layer below the insurer. DUOS, for example, bought Linkwell Health and said the combination would extend its AI-powered health-plan engagement platform across more than 20 health plans and reach one in five U.S. adults. The health plans remain customers while a specialist technology company does the consolidating.
Carenet Health, a services company working for health plans and providers, bought AI and data engineering consultancy Invene in October 2026. Carenet is a vendor, not an insurer. R1’s acquisition of Humata points to the same structure from the provider side. Prior authorization sits directly between insurers and providers, but an independent healthcare infrastructure company is buying the automation layer.
For now, insurers are not setting the pace of healthcare AI M&A.
Which healthcare AI buyers matter most, from Tempus to Agilent?
Tempus, Roche, Agilent, R1, Waystar, Azra AI and a growing group of AI-native care platforms are the healthcare AI buyers worth watching most closely. Most deal prices are undisclosed, so this is a list of active strategic buyers, not a spending ranking.
Tempus is probably the clearest example of an AI-native healthcare company turning into a consolidator. It bought pathology AI company Paige, then agreed to acquire Personalis for roughly $1.5 billion. The Personalis deal gives Tempus a larger position in molecular residual disease testing and lets it connect another cancer dataset to its existing multimodal data and AI platform.
Roche is approaching the market from the other direction. It already has enormous diagnostics distribution and can add specialized AI on top. Its agreement to acquire PathAI followed years of collaboration and came only weeks after another diagnostics purchase, SAGA Diagnostics.
Agilent is the newest large buyer, with its pending Proscia deal in digital pathology. Azra AI is consolidating imaging follow-up: after Thynk Health, it completed the Blackford Analysis deal on October 20, 2026.
R1 is now doing something similar in healthcare administration. Its planned Humata acquisition adds touchless AI prior authorization to R1’s existing revenue-management platform. Waystar previously made the same kind of move with Iodine Software.
AI-native care companies are also joining the buyer class. Doctronic bought Summer Health to add pediatric care to its AI-native primary-care platform. Included Health agreed to buy Firefly Health, adding primary care, health-plan capabilities and more than 2,300 in-person, in-home and specialty partners. Hinge Health agreed to pay $105 million for Cylinder Health, while Function Health previously bought AI-assisted MRI company Ezra and Sword Health bought Kaia Health for $285 million.
The buyer pool is widening from traditional healthcare incumbents to the strongest AI-enabled healthcare companies themselves.
| Buyer | Recent acquisition | Approximate value | What the deal adds |
|---|---|---|---|
| Tempus AI | Personalis | $1.5B enterprise value | MRD testing, oncology data and longitudinal cancer monitoring |
| Roche | PathAI | Up to $1.05B | AI pathology, laboratory workflow and biopharma diagnostics |
| Agilent | Proscia (pending) | $240M at closing, up to $270M | Pathology data and workflow layer used by 4,000+ labs, hospitals and clinics |
| Waystar | Iodine Software | $1.25B | Clinical documentation intelligence tied to reimbursement |
| R1 | Humata Health | Undisclosed | AI-powered prior authorization |
| Hinge Health | Cylinder Health | $105M | Digestive care added to an AI-enabled care platform |
| OpenAI | Torch | About $100M reported | Medical-record context for consumer healthcare AI |
When you build or invest in the healthcare AI market, you need clarity, not confusion. In our document detailing everything you need to know about healthcare AI, we always try to put numbers on and quantify whatever is usually vague and confusing.
Why is revenue-cycle AI getting bought so aggressively?
Revenue-cycle AI is one of the easiest healthcare AI categories for an acquirer to justify because buyers can connect the software directly to money recovered, labor removed or claims paid faster.
Waystar’s $1.25 billion acquisition of Iodine Software showed the scale this category can reach. Iodine was already used by more than 1,000 hospitals and health systems, while its technology had been trained on data representing more than one-third of U.S. inpatient discharges. Waystar could combine that clinical information with a platform processing billions of healthcare payment transactions.
Newer acquisitions show the category widening rather than cooling. Experity acquired Exdion to automate the chart-to-cash process for urgent care. R1 is adding Humata’s AI to prior authorization, one of the most frustrating steps before a claim even reaches payment. Med-Metrix has also been acquiring revenue-cycle assets, while Innovaccer has been folding more RCM capability into its platform. Prior authorization and denials are problems customers will pay to fix, and we look at which ones rank highest in our report covering the healthcare AI market.
The autumn 2026 deals pushed further into intake and paperwork: Hello Patient bought Converse Health, MRO bought Vyne Medical, whose document intake served more than 800 hospitals, and Zocdoc bought Sohar Health. Sagility signed a deal for coding services firm Chirok Health worth $20 million at closing and up to $32.35 million; its press release said the deal was done, but its October 22 filing said it had not closed.
The attraction is unusually concrete: lower denials, fewer staff hours and faster payment can be measured directly.
Why are pathology and diagnostics AI companies getting such big acquisition offers?
Diagnostics AI is producing some of the largest healthcare AI deals because good targets can come with a combination of proprietary medical data, regulated products and technology that fits directly into an existing diagnostics business.
Roche’s planned PathAI acquisition can reach $1.05 billion, with $750 million upfront and another $300 million tied to milestones. PathAI gives Roche AI-powered pathology analysis and laboratory workflow software that can sit alongside Roche’s existing diagnostics products.
Agilent’s agreement to buy Proscia is the newest price point: $240 million in cash at closing, plus up to $30 million if performance milestones are met. Proscia had trailing 12-month revenue above $18 million and serves more than 4,000 laboratories, hospitals and clinics, including 16 of the top 20 pharmaceutical companies. By our calculation, the closing price is at most about 13 times trailing revenue. The deal is expected to close early in Agilent’s fiscal 2027.
Tempus has been building from a different starting point. Its earlier Paige acquisition added pathology AI and access to a library approaching seven million digitized pathology slides. The planned $1.5 billion purchase of Personalis now pushes Tempus further into cancer monitoring through highly sensitive molecular residual disease testing.
GE HealthCare’s acquisition of icometrix followed the same broader logic in medical imaging. icometrix brought specialized neurological imaging software and regulated AI capabilities that GE could connect to an installed base of imaging equipment and hospital customers.
The underlying assets are unusually difficult to recreate. A new model can be trained surprisingly quickly these days. Rebuilding millions of clinically annotated images, obtaining regulatory clearances, convincing laboratories to change their workflow and building years of clinical evidence takes far longer.
| Target | Buyer | What is difficult to reproduce |
|---|---|---|
| PathAI | Roche | Digital pathology workflow, AI models, clinical adoption and biopharma relationships |
| Paige | Tempus | Large pathology-image library, pathology AI and regulatory work |
| icometrix | GE HealthCare | Neurological imaging algorithms, clinical validation and regulatory clearances |
| Personalis | Tempus | Oncology testing, longitudinal molecular data and MRD technology |
| Proscia | Agilent | Pathology data platform, lab workflow and pharma relationships |
In our report covering the healthcare AI market, we look at what the winners do differently, so you can learn from the best instead of guessing.
Will ambient AI scribe startups get acquired next?
Smaller ambient AI companies are obvious acquisition targets today, while the category leaders have already become expensive enough that buying them would require a major strategic bet.
Ambient documentation is a natural feature for EHR vendors, physician platforms and revenue-cycle companies. It sits inside the clinician’s daily workflow and can connect documentation directly to coding, orders and billing.
The problem for potential buyers is price. The leading independent companies have raised enormous amounts of capital. Abridge has reached a multibillion-dollar private valuation, and companies such as Ambience Healthcare have also raised large rounds. Acquiring one of the leaders would cost billions rather than the tens or hundreds of millions usually associated with a product tuck-in.
Smaller companies are easier to absorb. Cambio bought Leapscribe to add ambient documentation to its EHR ecosystem. Prompt acquired PredictionHealth, which uses AI around documentation, coding and compliance in rehabilitation care.
We found no prominent pure ambient-scribe acquisition announced in September or October 2026, and none of the leaders has said it is for sale. So consolidation looks more likely among smaller and mid-sized ambient AI companies than among the category leaders for now.
Are healthcare AI buyers really paying for the model?
Healthcare AI buyers increasingly care more about proprietary data, workflow access and customers than about owning another model.
The latest transactions make this easier to see. PathAI brings years of pathology work and an installed workflow. Personalis brings specialized cancer-testing technology and longitudinal molecular information. Humata brings a prior-authorization system that already knows how to operate across provider and payer processes. Iodine brought a massive hospital dataset and deep integration into clinical documentation. Blackford, now part of Azra AI, routes more than 130 AI applications from over 45 outside vendors rather than selling one model of its own.
Models have become easier to access as foundation-model quality improves. Healthcare data has moved in the opposite direction. High-quality pathology slides, claims histories, longitudinal patient records or properly labeled clinical data remain difficult to collect, expensive to clean and heavily constrained by privacy and regulation. Hard-to-collect data shapes who wins, and we study what leaders consistently do differently in our healthcare AI market report.
Distribution may be even more valuable. A startup that already sits inside 1,000 hospitals gives the buyer something that years of engineering cannot quickly recreate. The same applies to a company with a large physician network, a national laboratory footprint or integrations into major EHR systems.
A useful acquisition test is to imagine that the underlying model becomes widely available next year. If the startup still owns something hard to copy, the company can remain valuable. If everything disappears once competitors gain access to a similar model, the acquisition case gets much weaker.
In our research about AI in healthcare, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
Do healthcare partnerships like Agilent–Proscia end in acquisitions?
Yes, in a growing number of visible cases, and healthcare produces especially strong incentives for companies to work together before one decides to buy the other. Nobody publishes a conversion rate, though.
Roche and PathAI had been partners since 2021. Their collaboration widened in 2024 to include AI-enabled companion diagnostics, giving Roche years to see PathAI’s technology, team and workflow before agreeing to an acquisition.
Tempus followed an even more obvious path with Personalis. The companies began working together in 2023, Tempus invested in Personalis and commercialized its NeXT Personal cancer-monitoring test. By the time Tempus agreed to acquire the remaining company, it already knew how the product behaved inside its own commercial infrastructure.
Agilent and Proscia signed a multi-year distribution agreement in September 2022, four years before Agilent agreed to buy the company. Zocdoc used Sohar Health as a partner from 2025 before closing its acquisition in October 2026. Prompt’s acquisition of PredictionHealth also grew out of an existing relationship. These examples make sense in a sector where technical performance alone tells the buyer very little about how easily a product will survive real deployment.
Healthcare partnerships can test integration, physician adoption, data access, reimbursement and customer demand before the acquirer commits hundreds of millions of dollars. For startup founders, a large strategic partnership can quietly become part of the exit path long before anyone announces an M&A process.
Is private equity becoming a major healthcare AI buyer?
Private equity is becoming more involved in healthcare AI, but financial sponsors still sit behind strategic healthcare buyers in actual acquisition volume.
Rock Health calculated that PE firms accounted for about 10% of U.S. digital-health acquisitions in 2025. That was far below the 66% share taken by digital-health companies themselves, although PE spending on healthtech had risen sharply. Corum, cited by Fierce Healthcare, put private equity at 31% of healthtech deals in the first quarter of 2026; that counts a different set of deals, so the two shares are not comparable.
The strategy is also different. A PE firm often wants to combine a mature healthcare company with newer AI capabilities, improve margins and build a larger platform. Advent backed Iodine before Waystar ultimately bought it. Sopris Capital bought Blackford from Bayer on October 2, 2026, and moved it into its majority-owned Azra AI on October 20. Other sponsors have been pushing similar combinations across healthcare software and services.
The failed Thoreau project showed how ambitious this can get. New Mountain Capital tried to combine several healthcare technology businesses into an AI-focused platform reportedly valued around $32 billion, but the plan collapsed over financing and governance issues.
For now, strategic buyers remain more important because they usually have a specific operational reason to own the target.
Are healthcare AI acquisitions actually good exits for investors?
Healthcare AI M&A is creating more exits now, but a large acquisition price can still produce a mediocre venture return if the startup was valued too highly during the previous funding boom.
PathAI shows the issue clearly. The company reached a reported valuation of roughly $1.1 billion during the 2021 market peak. Roche’s current agreement offers $750 million upfront and up to $300 million more if milestones are achieved. Even the maximum consideration is around the valuation PathAI had already reached several years earlier.
Iodine tells a similar, although less severe, story. The company was valued around $1 billion in 2021 before Waystar eventually bought it for $1.25 billion. That is a substantial exit in absolute dollars, but the valuation did not multiply several times over. Exits below the old valuation change how investors see the market, and we examine where their money now goes in our report on healthcare AI.
Paige is an even harsher example. The company had raised well over $200 million before Tempus agreed to acquire it for an announced consideration of $81.25 million, although accounting values and the exact proceeds received by different shareholders make a simple capital-raised-versus-sale-price comparison imperfect.
Agilent’s Proscia deal gives a clear headline price, $240 million at closing and up to $270 million in total, but Proscia’s capital raised and investor proceeds are not public enough to calculate returns. Most other autumn 2026 deals had no disclosed price.
Healthcare AI now has a functioning buyer market, but investors who entered at peak private-market valuations are not automatically being rewarded for it.
In our market report about AI in healthcare, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
What kind of healthcare AI startup is most likely to get acquired now?
The easiest healthcare AI companies to buy today are deeply embedded in a valuable workflow, own something difficult to reproduce and fit naturally into a larger buyer’s existing distribution.
Revenue-cycle companies score well because the financial return is measurable. Diagnostics companies can bring proprietary clinical data and regulatory approvals. Workflow software can bring hospitals and physicians that the buyer already wants to reach. Small AI teams can also become attractive when their technology closes one specific gap inside a larger platform.
The autumn 2026 targets fit that profile: Proscia, Blackford, Lexi, Mila and Converse each plug into a workflow the buyer already sells.
Generic AI products face a tougher problem. If several competitors can recreate the core experience with the same foundation models, a buyer has little reason to purchase the whole company unless it wants the team or the customer base.
The latest market data supports this preference for embedded products. Galen Growth found B2B companies represented 47.6% of digital-health M&A in the first half of 2026, compared with 31.7% for B2C companies. B2B’s share has remained between roughly 46% and 53% in every first half since 2023, well above its 36.9% share in 2022.
| Startup profile | How attractive is it to buyers now? | What makes the asset valuable |
|---|---|---|
| AI embedded in revenue cycle or hospital operations | Very high | Clear ROI and existing enterprise workflow |
| Pathology, imaging or diagnostics AI | Very high | Proprietary clinical data, regulation and scarce expertise |
| AI with a large healthcare customer base | Very high | Buyer gets distribution immediately |
| AI tied to proprietary longitudinal data | High | Dataset improves as usage grows |
| Ambient AI with strong physician adoption | High, but expensive at the top | Daily workflow and valuable clinical data |
| Narrow AI product using widely available models | Much lower | Core technology can often be reproduced |
So who’s buying healthcare AI startups?
Healthcare AI startups are currently being bought mainly by healthcare companies that already control a valuable piece of the system: software platforms, diagnostics groups, medtech companies and a newer class of AI-native health platforms.
The numbers and the newest deals line up unusually well. Rock Health found that digital-health companies accounted for 66% of U.S. digital-health acquisitions in 2025, the highest share it has recorded. Galen Growth found M&A represented almost every digital-health exit in its first-half 2026 dataset.
The buyer list has kept widening. In October 2026, Agilent agreed to buy Proscia for pathology, Azra AI completed its Blackford Analysis deal in imaging and Equiti bought Lexi for AI interpretation. In September, DexCare bought Mila Health and Hello Patient bought Converse Health to extend AI agents in patient access. Earlier in 2026, R1 agreed to buy Humata to automate prior authorization, Tempus agreed to buy Personalis to deepen cancer monitoring and Roche agreed to buy PathAI to strengthen digital pathology.
Big Tech remains the wildcard. OpenAI’s Torch acquisition shows how a frontier AI company can buy healthcare-specific infrastructure rather than building everything internally. So far, however, we have not seen Google, Amazon, Microsoft, OpenAI or other horizontal technology companies buying healthcare AI startups at anything close to the frequency of healthcare-native buyers.
Hospitals mostly remain customers and validation partners. Insurers are using AI heavily but are still relatively quiet as direct acquirers. Private equity is funding and assembling platforms, although it remains secondary to strategic buyers.
The most useful way to predict the next healthcare AI acquisition is to look at the buyer first. Find a company that already owns hospital access, physician attention, diagnostic distribution, claims infrastructure or a large patient base. Then look for the AI startup that fills the most expensive missing piece.
That is where healthcare AI M&A is happening today.
Our methodology
The main question here does not have a clean answer in a single dataset. “Who’s buying healthcare AI startups?” changes depending on whether we look at buyer type, deal volume, subsector, transaction size, strategic rationale or the assets buyers are actually trying to acquire. We therefore broke the question into those dimensions and assessed them separately before drawing the broader conclusion.
For each dimension, we prioritized recent evidence: 2025 and 2026 M&A datasets, including sector counts through September 2026, newly announced acquisitions, disclosed transaction values, buyer activity, sector concentration, partnerships that preceded acquisitions and the strategic rationale given by the companies themselves. Individual deals count as evidence when they reinforce what the aggregate data shows, not because they are large.
Where datasets use different scopes or definitions, we did not merge them into one artificial total. Rock Health is used primarily for U.S. digital-health acquisition activity and buyer mix, while Galen Growth provides a broader view of digital-health exits, strategic-buyer behavior, B2B concentration and healthcare-infrastructure activity. We compare the direction and strength of those findings rather than treating unlike datasets as interchangeable.
We also distinguish between healthcare AI as a product category and AI as a capability embedded inside a broader healthcare company. That is why the analysis includes deals such as Tempus–Personalis or Included Health–Firefly Health when AI is central to the buyer’s platform or acquisition rationale, even if the target itself is not marketed as a pure AI startup.
Key sources include Rock Health’s 2025 year-end digital-health overview, Galen Growth’s H1 2026 digital-health exits analysis, Galen Growth’s work on healthcare infrastructure M&A, Agilent on its agreement to acquire Proscia, Azra AI’s release on Blackford Analysis, Let’s Data Science on the Sopris and Azra AI transactions, and HIT Consultant on DexCare and Mila Health.
For individual transactions, we favored first-hand company announcements and regulatory filings. The main deal sources include R1 on Humata Health, Roche on PathAI, Tempus on Personalis, Tempus’s SEC filing on the Personalis transaction, Waystar on Iodine Software, GE HealthCare’s filing covering icometrix, Included Health on Firefly Health, and Hinge Health on Cylinder Health.
For deals where primary disclosure was limited, we used specialist or tier-one reporting rather than treating reported figures as company-confirmed. That includes Axios on OpenAI’s acquisition of Torch, alongside OpenAI’s healthcare product strategy and OpenAI’s Health in ChatGPT announcement for strategic context.
The final conclusions are therefore based on the weight and consistency of the evidence across several dimensions, not on a mechanical score.
Our document detailing everything you need to know about healthcare AI gets updated several times a month, so you always get the latest view of where things stand.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us